The Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI) have reached an agreement
on the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG).
The landmark deal will save the NHS £14 billion over 5 years in medicines costs, boost the nation's health, and support research investment.
The new VPAG scheme, which will be a non-contractual voluntary agreement between DHSC and ABPI, will run for 5 years from 1 January 2024 until 31 December 2028.
It will double the annual allowed growth of sales of branded medicines from two per cent per year in 2024 to four per cent per year by 2027.